Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Trimmed by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 56,011 shares of the biopharmaceutical company's stock after selling 4,490 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Alnylam Pharmaceuticals were worth $15,124,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $243,000. Jones Financial Companies Lllp purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $63,000. Charles Schwab Investment Management Inc. boosted its position in Alnylam Pharmaceuticals by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,962 shares of the biopharmaceutical company's stock valued at $120,940,000 after buying an additional 26,614 shares during the last quarter. Keybank National Association OH purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $673,000. Finally, Assetmark Inc. boosted its position in Alnylam Pharmaceuticals by 9.2% in the fourth quarter. Assetmark Inc. now owns 10,033 shares of the biopharmaceutical company's stock valued at $2,361,000 after buying an additional 847 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Chardan Capital upped their target price on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the company an "equal weight" rating in a research report on Monday, June 30th. Royal Bank Of Canada upped their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research report on Friday, March 21st. Finally, Needham & Company LLC upped their price objective on Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-two have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $341.91.

Alnylam Pharmaceuticals Stock Down 2.0%

ALNY traded down $6.63 on Tuesday, reaching $317.50. The company's stock had a trading volume of 972,968 shares, compared to its average volume of 856,566. The stock has a market cap of $41.40 billion, a price-to-earnings ratio of -151.91 and a beta of 0.23. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $333.70. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. The business's 50 day moving average is $296.35 and its 200 day moving average is $267.00.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company's quarterly revenue was up 20.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.16) EPS. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the sale, the chief executive officer directly owned 48,948 shares in the company, valued at $14,978,088. This trade represents a 28.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.